Anti-HACE1 antibody [EPR7962]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

HACE1 also known as HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase 1 is a protein with a mass of approximately 111 kDa. This protein functions as an E3 ubiquitin ligase facilitating the attachment of ubiquitin molecules to specific protein substrates marking them for degradation via the proteasome pathway. It achieves this by recognizing and binding to substrates through its ankyrin repeat domains and catalyzing the conjugation process using its HECT domain. HACE1 is ubiquitously expressed in various tissues including the brain kidney and heart indicating its broad cellular importance.

Biological function summary

HACE1 plays a role in regulating cellular processes such as apoptosis cell cycle and oxidative stress response contributing to normal cellular homeostasis. It impacts signaling pathways by tagging proteins involved in these processes for degradation ensuring proper cell function and survival. HACE1 functions as part of a ubiquitin-proteasome complex that finely tunes cell signaling cascades through selective protein turnover. Its activity helps maintain a balanced level of critical proteins within the cell influencing cellular proliferation and survival.

Pathways

Several important cellular processes involve HACE1 including the oxidative stress response and cell cycle regulation pathways. Within these pathways HACE1 interacts with proteins like RAC1 a small GTPase associated with ROS production and cellular growth control. By modulating RAC1 and other related proteins HACE1 contributes to maintaining the redox balance and ensuring proper cell cycle progression. This interaction highlights HACE1's role in safeguarding cellular integrity under variable conditions.

Associated diseases and disorders

HACE1 has been linked to Wilms' tumor and neurodegenerative diseases. In cancer the loss of HACE1 function results in unchecked cellular proliferation and tumor development marking it as a potential tumor suppressor. The protein's downregulation or mutation is often observed in Wilms' tumor where it interacts with pathways involving TP53 another significant tumor suppressor. In the context of neurodegenerative diseases HACE1's role in managing oxidative stress suggests a connection with disorders such as Parkinson’s disease where oxidative damage is a critical pathogenic factor.